Array BioPharma

Array BioPharma is a U.S.-based, clinical stage, publicly traded pharmaceutical company founded in Boulder, Colorado (NASDAQ:ARRY) that is included in the NASDAQ Biotechnology Index.The company has engaged in collaborations with Pfizer and Merck to study several cancer targeting drug combinations. In July 2013 the company partnered with Loxo Oncology to develop cancer drugs, in November 2015 the company partnered with Pierre Fabre and the company also partnered with Ono Pharmaceutical in March 2016 to test the combination of binimetinib and encorafenib while retaining commercialization rights in the U.S. and other markets.In 2017 it spun out one of its programs into a subsidiary called Yarra; the asset was a molecule called ARRY-797 that was in a Phase II trial for cardiomyopathy.In March 2018 Array sued AstraZeneca for breach of contract, saying that AZ owed it a 12% royalty on a portion of the $1.6 billion upfront payment that Merck had paid to AZ in a deal for selumetinib, which Array said it had licensed to AZ in 2003.In June 2018, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) were approved by the FDA for the treatment of people with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma. UpGuard continuously monitors the security posture of Array BioPharma using open-source, commercial, and proprietary threat intelligence feeds. Our analysis is centered on objective, externally verifiable information.

Array BioPharma Security Rating

/ 950
Array BioPharma's security rating is based on the analysis of their external attack surface. The higher the rating, the better their security posture. Start a free trial to get a more in-depth risk assessment for Array BioPharma.

Company info

Array BioPharma
Array BioPharma
Last updated
Last updated
Last updated today

Array BioPharma Vendor Risk Report

This vendor risk report is based on UpGuard’s continuous monitoring of Array BioPharma's security posture using open-source, commercial, and proprietary threat intelligence feeds. The results are summarized into a security rating based on the analysis of hundreds of individual checks across five risk categories: website security, email security, phishing & malware, brand & reputation risk, and network security.

Last updated today

Array BioPharma Data Breaches, Cybersecurity Incidents and News

Security incidents, news, and data leaks relating to Array BioPharma.

Security reports related to Array BioPharma

Compare Array BioPharma's security performance with other companies in their industry.

#1 Third Party & Supplier Risk Management Software

See how UpGuard shapes up against other platforms in the market.
Free instant security score

How secure is your organization?

Request a free cybersecurity report to discover key risks on your website, email, network, and brand.
  • Check icon
    Instant insights you can act on immediately
  • Check icon
    Hundreds of risk factors including email security, SSL, DNS health, open ports and common vulnerabilities
Website Security scan resultsWebsite Security scan rating
Want a complete vendor risk report on this company?
Our comprehensive vendor risk report is based on this company's external attack surface and provides actionable insights, industry benchmarking, and historical trends.